Oruka Therapeutics, Inc.
ORKA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 1.19 | 0.82 | -0.19 |
| FCF Yield | -17.82% | 0.00% | -2.66% | -5.24% |
| EV / EBITDA | -3.22 | -49.15 | -37.48 | -15.90 |
| Quality | ||||
| ROIC | -23.00% | -19.56% | -23.40% | -37.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 1.10 | 0.97 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 41.96% | -142.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.74 | 7.11 | 4.29 | 2.75 |
| Interest Coverage | -60.03 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -46,801.11 | 0.00 | -1,069.39 | -4,480.27 |